Alligator Bioscience AB intends to list its shares on Nasdaq Stockholm

Alligator Bioscience AB (“Alligator” or the “Company”), a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy, announced on November 2, 2016 its intention to list the Company’s shares on Nasdaq Stockholm. Today, the Company publishes the prospectus for the offering (the “Offering”).

 

The offering in summary

Price interval 32,50 SEK per share
Application period for the public in Sweden 15 November - 22 November 2016
Application period for institutional investors 15 November - 22 November 2016
First day of trading 23 November 2016
Settlement date 25 November 2016

Contact

For more information please contact:

 

g-piir

Rein Piir
VP Investor Relations
Phone: +46 708 53 72 92
Email: rpr@alligatorbioscience.com